173 related articles for article (PubMed ID: 29862242)
1. Traditional Chinese medicine Qiliqiangxin attenuates phenylephrine-induced cardiac hypertrophy via upregulating PPARγ and PGC-1α.
Gao RR; Wu XD; Jiang HM; Zhu YJ; Zhou YL; Zhang HF; Yao WM; Li YQ; Li XL
Ann Transl Med; 2018 Apr; 6(8):153. PubMed ID: 29862242
[TBL] [Abstract][Full Text] [Related]
2.
Cheng H; Wu X; Ni G; Wang S; Peng W; Zhang H; Gao J; Li X
Ann Transl Med; 2020 Nov; 8(21):1396. PubMed ID: 33313141
[TBL] [Abstract][Full Text] [Related]
3. Traditional Chinese Medication Qiliqiangxin Protects Against Cardiac Remodeling and Dysfunction in Spontaneously Hypertensive Rats.
Wang H; Zhang X; Yu P; Zhou Q; Zhang J; Zhang H; Zhu H; Zhang C; Yao W; Che L; Xu J; Bei Y; Li X
Int J Med Sci; 2017; 14(5):506-514. PubMed ID: 28539827
[TBL] [Abstract][Full Text] [Related]
4. Traditional Chinese Medication Qiliqiangxin Attenuates Diabetic Cardiomyopathy via Activating PPARγ.
Wu X; Zhang T; Lyu P; Chen M; Ni G; Cheng H; Xu G; Li X; Wang L; Shang H
Front Cardiovasc Med; 2021; 8():698056. PubMed ID: 34336956
[No Abstract] [Full Text] [Related]
5. Qiliqiangxin: A multifaceted holistic treatment for heart failure or a pharmacological probe for the identification of cardioprotective mechanisms?
Packer M
Eur J Heart Fail; 2023 Dec; 25(12):2130-2143. PubMed ID: 37877337
[TBL] [Abstract][Full Text] [Related]
6.
Ni G; Wang K; Zhou Y; Wu X; Wang J; Shang H; Wang L; Li X
Ann Transl Med; 2020 Sep; 8(17):1064. PubMed ID: 33145283
[TBL] [Abstract][Full Text] [Related]
7. Qiliqiangxin Attenuates Adverse Cardiac Remodeling after Myocardial Infarction in Ovariectomized Mice via Activation of PPARγ.
Shen S; Jiang H; Bei Y; Zhang J; Zhang H; Zhu H; Zhang C; Yao W; Wei C; Shang H; Li X
Cell Physiol Biochem; 2017; 42(3):876-888. PubMed ID: 28647730
[TBL] [Abstract][Full Text] [Related]
8. Traditional Chinese Medication Qiliqiangxin attenuates cardiac remodeling after acute myocardial infarction in mice.
Tao L; Shen S; Fu S; Fang H; Wang X; Das S; Sluijter JP; Rosenzweig A; Zhou Y; Kong X; Xiao J; Li X
Sci Rep; 2015 Feb; 5():8374. PubMed ID: 25669146
[TBL] [Abstract][Full Text] [Related]
9. The Metabolic Effects of Traditional Chinese Medication Qiliqiangxin on H9C2 Cardiomyocytes.
Lin S; Wu X; Tao L; Bei Y; Zhang H; Zhou Y; Shen S; Xiao J; Li X
Cell Physiol Biochem; 2015; 37(6):2246-56. PubMed ID: 26618786
[TBL] [Abstract][Full Text] [Related]
10. Qiliqiangxin Attenuates Phenylephrine-Induced Cardiac Hypertrophy through Downregulation of MiR-199a-5p.
Zhang H; Li S; Zhou Q; Sun Q; Shen S; Zhou Y; Bei Y; Li X
Cell Physiol Biochem; 2016; 38(5):1743-51. PubMed ID: 27161004
[TBL] [Abstract][Full Text] [Related]
11. Nobiletin Attenuates Pathological Cardiac Remodeling after Myocardial Infarction via Activating PPAR
Zhou Y; Yin T; Shi M; Chen M; Wu X; Wang K; Cheang I; Li Y; Shang H; Zhang H; Li X
PPAR Res; 2021; 2021():9947656. PubMed ID: 34422028
[TBL] [Abstract][Full Text] [Related]
12. Qiliqiangxin Attenuates Oxidative Stress-Induced Mitochondrion-Dependent Apoptosis in Cardiomyocytes via PI3K/AKT/GSK3β Signaling Pathway.
Zhao Q; Li H; Chang L; Wei C; Yin Y; Bei H; Wang Z; Liang J; Wu Y
Biol Pharm Bull; 2019 Aug; 42(8):1310-1321. PubMed ID: 31142701
[TBL] [Abstract][Full Text] [Related]
13. Qiliqiangxin reduced cardiomyocytes apotosis and improved heart function in infarcted heart through Pink1/Parkin -mediated mitochondrial autophagy.
Zhou J; Wang Z; He Y; Luo X; Zhang W; Yu L; Chen X; He X; Yuan Y; Wang X; Guo X; Tang J; Zhu M; Li D; Ding Y
BMC Complement Med Ther; 2020 Jul; 20(1):203. PubMed ID: 32615967
[TBL] [Abstract][Full Text] [Related]
14. Novel PGC-1
Zhang B; Tan Y; Zhang Z; Feng P; Ding W; Wang Q; Liang H; Duan W; Wang X; Yu S; Liu J; Yi D; Sun Y; Yi W
Oxid Med Cell Longev; 2020; 2020():9187065. PubMed ID: 33425220
[TBL] [Abstract][Full Text] [Related]
15. Astragaloside IV protects against isoproterenol-induced cardiac hypertrophy by regulating NF-κB/PGC-1α signaling mediated energy biosynthesis.
Zhang S; Tang F; Yang Y; Lu M; Luan A; Zhang J; Yang J; Wang H
PLoS One; 2015; 10(3):e0118759. PubMed ID: 25738576
[TBL] [Abstract][Full Text] [Related]
16. Astragalus polysaccharide attenuates isoproterenol-induced cardiac hypertrophy by regulating TNF-α/PGC-1α signaling mediated energy biosynthesis.
Luan A; Tang F; Yang Y; Lu M; Wang H; Zhang Y
Environ Toxicol Pharmacol; 2015 May; 39(3):1081-90. PubMed ID: 25880160
[TBL] [Abstract][Full Text] [Related]
17. Qiliqiangxin Protects against Renal Injury in Rat with Cardiorenal Syndrome Type I through Regulating the Inflammatory and Oxidative Stress Signaling.
Duan X; Yan F; Hu H; Liu H; Wu Q; Sun S; Ming X; Bu X; He Y; Zhu H
Biol Pharm Bull; 2018; 41(8):1178-1185. PubMed ID: 30068867
[TBL] [Abstract][Full Text] [Related]
18. AdipoRon prevents l-thyroxine or isoproterenol-induced cardiac hypertrophy through regulating the AMPK-related pathway.
Hu X; Ou-Yang Q; Wang L; Li T; Xie X; Liu J
Acta Biochim Biophys Sin (Shanghai); 2019 Jan; 51(1):20-30. PubMed ID: 30566571
[TBL] [Abstract][Full Text] [Related]
19. A CRM1 Inhibitor Alleviates Cardiac Hypertrophy and Increases the Nuclear Distribution of NT-PGC-1α in NRVMs.
Liu Z; Tian H; Hua J; Cai W; Bai Y; Zhan Q; Lai W; Zeng Q; Ren H; Xu D
Front Pharmacol; 2019; 10():465. PubMed ID: 31133853
[TBL] [Abstract][Full Text] [Related]
20. Qiliqiangxin prevents right ventricular remodeling by inhibiting apoptosis and improving metabolism reprogramming with pulmonary arterial hypertension.
Lu Y; Wu J; Sun Y; Xin L; Jiang Z; Lin H; Zhao M; Cui X
Am J Transl Res; 2020; 12(9):5655-5669. PubMed ID: 33042446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
